The KOL provides insights into epidemiology, prescribing habits, key marketed brands, and late-phase pipeline therapies for NSCLC. Treatment strategies split by various mutational statuses and disease stages as well as unmet needs are also discussed. Key pipeline assets highlighted include tiragolumab, domvanalimab, ociperlimab, Libtayo + fianlimab, tislelizumab, Dato-DXd, and olomorasib. 

This interview was conducted on 15 April 2024. 

If you are a KOL Insight Subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.